Biogen Aktie

118,90 EUR -2,00 EUR -1,65 %

20:11:29

STU

131,00 USD -0,32 USD -0,24 %

20:47:05

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.17,49 Mrd. EUR

KGV13,67Div. Rendite0,00%

WKN789617

ISINUS09062X1037

SymbolBIIB

Biogen Aktien News

Sortieren:Datum Meistgelesen

20.07.23GlobeNewswireEisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

07.07.23PR NewswireFDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

07.07.23GlobeNewswireFDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

30.06.23GlobeNewswireNew Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

12.06.23GlobeNewswireBiogen Announces Changes to Its Board of Directors

10.06.23PR NewswireFDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

10.06.23GlobeNewswireFDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

16.05.23GlobeNewswireHealth Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

25.04.23GlobeNewswireFDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

31.03.23PR NewswireADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS

31.03.23PR NewswireEISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING

31.03.23GlobeNewswireEisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

31.03.23GlobeNewswireAdditional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

29.03.23GlobeNewswireNew Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

23.03.23GlobeNewswireBiogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

16.03.23GlobeNewswireBiogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

08.03.23GlobeNewswireCaroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

06.03.23PR NewswireFDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

06.03.23GlobeNewswireFDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

28.02.23PR NewswireBIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

28.02.23GlobeNewswireBiologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

30.01.23PR NewswireLECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN

27.01.23PR NewswireMARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY

16.01.23PR NewswireEISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN

11.01.23PR NewswireEISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

07.01.23PR NewswireEisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

06.01.23PR NewswireFDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

23.12.22PR NewswireEISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA

30.11.22PR NewswireEISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

30.11.22PR NewswireELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGL...

21.11.22RSSForm 3 875045

10.11.22GlobeNewswireBiogen Names Christopher Viehbacher President and Chief Executive Officer

10.11.22RSSForm 8-K 875045

28.10.22RSSForm 4 875045

26.10.22GlobeNewswireBiogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

26.10.22GlobeNewswireNew Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS

25.10.22RSSForm 10-Q 875045

25.10.22RSSForm 8-K 875045

17.10.22GlobeNewswireBiogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

13.10.22PR NewswireSHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm

Biogen News

Biogen News: auf dieser Seite finden Sie alle Biogen News und Nachrichten zur Biogen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biogen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biogen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.